Skip to content
← The Index board

Promising · 6.3/10

NMN (Nicotinamide Mononucleotide)

Evidence D · early evidence ▲ 62.5% momentum 🥇 First scout open
6.3/ 10

NMN is an oral NAD+ precursor that reliably raises blood NAD+ in human trials, but clinical benefits remain modest and endpoint-limited. Yoshino 2021 found a 25% muscle insulin-sensitivity gain in 25 prediabetic postmenopausal women, while 2024-2026 meta-analyses found mostly null glucose and lipid effects in broader adult samples. Read the full breakdown →

The prediction game

Where does NMN (Nicotinamide Mononucleotide) go in 12 months?

Lock a call and say how sure you are. Right and confident earns the most; a leaderboard spot is the prize. No money, no stakes.

The Crowd’s Call

Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.

Your 12-month call on NMN (Nicotinamide Mononucleotide)

New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.

Be the first scout on record for NMN (Nicotinamide Mononucleotide). Permanent credit on this page, plus points when your call resolves.

One call per intervention. It locks the moment you submit (no edits, no cancels) and resolves in 12 months. See the scout leaderboard →

Weigh In

Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.

Tried it in real life?

Which ring does it deserve?

Same as above — one verification covers all your entries here.

Related reading

Ring Promising Momentum 62.5% Updated Jul 20, 2026 How the Index ranks →

Verdict by Nick Urban, host of the High Performance Longevity podcast.

For education only, not medical advice. Supplements, peptides, and protocols can interact with medications and conditions. Talk to a qualified clinician before starting anything here.